New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:00 EDTANET, SRPT, SGMO, RNA, BIN, PZG, PTCT, FLML, FINL, CBAY, CWST, SCMPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
News For ANET;CWST;CBAY;FINL;FLML;PTCT;PZG;BIN;RNA;SGMO;SRPT;SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 23, 2014
15:25 EDTSRPTNew York confirms health care worker being tested for Ebola
Subscribe for More Information
14:58 EDTSRPTNew York doctor rushed to hospital with Ebola-like symptoms, NY Post reports
Subscribe for More Information
06:22 EDTSRPTEU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
05:41 EDTPZGParamount Gold & Silver intersects high-grade gold at San Miguel
Paramount Gold and Silver announced that the second drill hole on the newly discovered Dana structure at its 100%-owned San Miguel Project in northern Mexico has intersected high gold grades in addition to the significant silver grades found in the discovery hole released last week. The first hole drilled into Dana, DN-001, returned multiple intercepts of high grade silver with lower grades of gold including 3.6 meters of 157.1 grams per tonne of silver and 0.40 g/T of gold containing assays up to 659 g/T of silver and 1.18 g/T gold. Paramount geologists believed that gold grades would increase at lower elevations similar to the nearby, high grade, Don Ese deposit which it resembles. DN-002 was drilled along strike 100 meters northwest of DN-001 to intersect the Dana structure 50 meters deeper. DN-002 cut a stock work zone with internal silicified breccia totaling 5.4 meters and grading an average of 3.79 g/T gold and 183 g/T silver, which amounts to a 6.84 g/T gold equivalent grade using a gold-to-silver ratio of 1 to 60. The new Dana discovery runs 400-500 meters southwest of the Don Ese structure and parallel to it, and has a strike length potential on Paramount ground of about one kilometer. Don Ese is the highest grade and most valuable gold/silver deposit at San Miguel. The location of Dana favors early development from underground in parallel with Don Ese. Paramount has made Dana a top priority for resource expansion by immediately moving a second core rig onto this target. Dana is just 800 meters northeast of Coeur Mining's Guadalupe underground mine currently under development at its flagship Palmarejo Project. Guadalupe is expected to become the main source of ore for the Palmarejo operation. See the map below.
October 22, 2014
16:12 EDTSGMOSangamo backs FY14 revenue view $45M-$50M, consensus $47.57M
Subscribe for More Information
16:06 EDTSGMOSangamo reports Q3 EPS (11c), consensus (14c)
Subscribe for More Information
06:41 EDTSRPTWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
06:08 EDTANETArista Networks expands leaf switch product portfolio
Subscribe for More Information
October 21, 2014
18:02 EDTSCMPSucampo, Takeda enter into global licensing agreement for AMITIZA
Subscribe for More Information
07:32 EDTFINLFinish Line names Samuel Sato as president
Subscribe for More Information
05:12 EDTPZGParamount substantially expands San Francisco bulk tonnage potential
Subscribe for More Information
October 20, 2014
14:55 EDTCWSTPortolan Capital reports 5.19% passive stake in Casella Waste
Subscribe for More Information
09:09 EDTSRPTEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
08:11 EDTFINLFinish Line management to meet with Deutsche Bank
Meeting to be held in New York on October 20 hosted by Deutsche Bank.
06:50 EDTRNAProsensa upgraded to Overweight from Underweight at JPMorgan
JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.
October 19, 2014
16:44 EDTSRPTEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTSRPTCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTSRPTBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTSRPTSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
09:17 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use